×

Biotech Analyst Bullish on BIIB

5:41 PM ET Mon, 20 June 2011

Mark Schoenebaum, ISI Group analyst, explains how BIIB can triple its dividend in three years. "This growth exists nowhere else in large cap pharma or biotech," he says.